Cardiovascular and Neurological Complications Associated with Atrial Fibrillation

  • Raymond Pranata Faculty of Medicine, Pelita Harapan University, Tangerang
  • Hadrian Deka Faculty of Medicine, Gadjah Mada University, Yogyakarta
  • Bambang Budi Siswanto

Abstract

Atrial fibrillation (FA) is the most common type of sustained-arrhythmia and one of the leading causes of mortality and morbidity globally, with estimated five million incidents. FA was associated with increased all-cause mortality (RR 1.46), cardiovascular mortality (RR 2.03), major cardiovascular events (RR 1.96), stroke (RR 2.42), ischemic stroke (RR 2.33), dementia (HR 1.42) and cognitive decline, ischemic heart disease (RR 1.61), sudden cardiac death (RR 1.88), heart failure (RR 4.99), chronic kidney disease (RR 1.64), and peripheral artery disease (RR 1.31). Overall, all-cause and cardiovascular mortality increased. Cognitive decline and dementia are also a concern since they impair function and quality of life. Overall, FA has bidirectional association with other cardiovascular diseases hence it acts as a marker for them. Therefore, prevention and control of risk factors are of utmost importance.

Downloads

Download data is not yet available.

References

Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-47.

Wyndham CR. Atrial fibrillation: the most common arrhythmia. Tex Heart Inst J. 2000; 8:257–267.

Conen D, Chae CU, Glynn RJ, et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA. 2011;305:2080-7.

Rasekh A. Anticoagulants and atrial fibrillation. Tex Heart Inst J. 2005;32(2):218–219.

Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006;119:448.e1-19.

January CT, Wann LS, Alpert JS, et al. ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071-104.

Kirchhof P, Benussi S, Kotecha D, et al on behalf of Authors/Task Force Members. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016. pii:euw 295.

Odutayo A, Wong CX, Hsiao AJ, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482.

Soliman EZ, Lopez F, O’Neal WT, et al. Atrial fibrillation and risk of ST-segment-elevation versus non-ST-segment-elevation myocardial infarction: The atherosclerosis risk in communities (ARIC) study. Circulation. 2015;131:1843-50.

Soliman EZ, SFAford MM, Muntner P, et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014;174:107-14.

O’Neal WT, Sangal K, Zhang Z-M, Soliman EZ. Atrial fibrillation and incident myocardial infarction in the elderly. Clin Cardiol. 2014;37:750-5.

Bansal N, Fan D, Hsu CY, et al. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation. 2013;127:569-74.

de Bruijn RFAG, Heeringa J, Wolters FJ, et al. Association between atrial fibrillation and dementia in the general population. JAMA neurology. 2015;72:1288–1294.

Alonso A, Arenas AP. Atrial fibrillation, cognitive decline and dementia. Eur Cardiol. 2016 Summer; 11(1):49–53.

Guiterrez C, Blanchard DG. Atrial fibrillation: Diagnosis and treatment. Am Fam Physician. 2011;83(1):61-68.

Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA: the journal of the American Medical Association. 2001;285:2370-5.

Yuniadi Y, Tondas AE, Hanafy DA, et al. Pedoman tata laksana fibrilasi atrium. PERKI 2016.

Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol. 1998 Oct 16. 82(8A):2N-9N.

Damayanti BP, Limantoro C. Hubungan antara hipertensi dan hipertrofi ventrikel kiri pada pasien lansia dengan atrial fibrilasi. Diss. Fakultas Kedokteran Universitas Diponegoro, 2014.

Atrial fibrillation clinical presentation. 2013. Tersedia di http://emedicine. medscape.com/article/151066-clinical. Diakses pada 18 September 2016.

Marzona I, O’Donnell M, Teo K, et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CMAJ. 2012;184:E329–E336.

Chen LY, Lopez FL, Gottesman RF, et al. Atrial fibrillation and cognitive decline–the role of subclinical cerebral infarcts: The atherosclerosis risk in communities study. Stroke. 2014;45:2568–2574.

Efimova I, Efimova N, Chernov V, et al. Ablation and pacing: improving brain perfusion and cognitive function in patients with atrial fibrillation and uncontrolled ventricular rates. Pacing Clin Electrophysiol. 2012;35:320–326.

Di Nisio M, Prisciandaro M, Rutjes AWS, et al. Dementia in patients with atrial fibrillation and the value of the Hachinski ischemic score. Geriatr Gerontol Int. 2015;15:770–777.

Habeych ME, Castilla-Puentes R. Comorbid medical conditions in vascular dementia: A matched case-control study. J Nerv Ment Dis. 2015;203:604–608.

Jacobs V, May HT, Bair TL, et al. Long-term population-based cerebral ischemic event and cognitive outcomes of direct oral anticoagulants compared with warfarin among long-term anticoagulated patients for atrial fibrillation. Am J Cardiol 2016 May 5; doi: 10.1016/j.amjcard.2016.1004.1039.

Soliman EZ, SFAford MM, Muntner P, et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014;174:107-14.

Chen LY, Sotoodehnia N, Bužková P, et al. Atrial fibrillation and the risk of sudden cardiac death: The atherosclerosis risk in communities study and cardiovascular health study. JAMA Intern Med. 2013;173:29-35.

Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: Treatment considerations for a dual epidemic. Circulation. 2009;119:2516–2525.

Watanabe H, Watanabe T, Sasaki S, et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: The Niigata preventive medicine study. Am Heart J. 2009;158(4):629–636.

Tsiachris D, Tsioufis C, Mazzone P, et al. Atrial fibrillation and chronic kidney disease in hypertension: A common and dangerous triad. Curr Vasc Pharmacol. 2015;13(1):111-20.

Bansal N, Fan D, Hsu CY, et al.. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation. 2013;127(5):569-574.

Santangeli P, Di Biase L, Bai R, et al. Atrial fibrillation and the risk of incident dementia: A meta-analysis. Heart Rhythm. 2012;9:1761–1768.e1762.

Joundi RA, Cipriano LE, Sposato LA, Saposnik G. Stroke Outcomes Research Working, Group (May 2016). “Ischemic stroke risk in patients with atrial fibrillation and CHA2DS2-VASc score of 1: Systematic review and meta-Analysis.”. Stroke; a journal of cerebral circulation. 2016;47(5):1364–7. doi: 10.1161/strokeaha.115.012609.PMID 27026630.

Carrero JJ, de Jager DJ, Verduijn M, et al. Cardiovascular and noncardiovascular mortality among men and women starting dialysis. CJASN. 2011;6(7):1722-1730.

“What is a stroke?” www.nhlbi.nih.gov/. March 26, 2014. Retrieved 26 February 2015.

Lilli LS. Pathophysiology of heart disease: A collaborative project of medical students and faculty. Baltimore: LWW;2011.

Published
2017-04-18

Abstract viewed :
104 times
PDF downloaded : 188 times

How to Cite
Pranata, R., Deka, H., & Siswanto, B. (2017). Cardiovascular and Neurological Complications Associated with Atrial Fibrillation. Indonesian Journal of Cardiology, 37(3), 164-72. https://doi.org/10.30701/ijc.v37i3.580
Section
Review Article